Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer

Inclusion Criteria: * Histologically or cytologically confirmed stage IIIB/IV NSCLC patients progressing after first-line chemotherapy; * Patients must have stopped prior platinum-based therapy at least four weeks prior to enroll and fully recovered from chemotherapy-induced toxicity; * Age: 18-70 years old; * Patients with wild-type EGFR; * With a histologically or cytologically confirmed measurable disease (longest diameters \>=10mm with Spiral computed tomography (CT)and \>=20mm with conventional CT) according to Response Evaluation Criteria in Solid Tumors (RECIST Criteria); * Patients must have Eastern Cooperative Oncology Group(ECOG)Performance Status of 0-2; * Must have an expected survival time of at least 12 weeks; * Patients should have adequate bone marrow function defined as an absolute peripheral neutrophil count (ANC) of ≥1.5 ´ 109/L, platelet count of ≥ 75´ 109/L; Hemoglobin(Hb) ≥ 9g/dL; * adequate hepatic function: bilirubin ≤2x the upper limit of normal, glutamic-oxaloacetic transaminase(AST )and glutamate pyruvate transaminase(ALT)≤2x the upper limit of normal (≤5x the upper limit of normal if evidence of liver metastases); * adequate renal function: bilirubin serum creatinine ≤1.5 x the upper limit of normal; * No malabsorption or other gastrointestinal disorders affecting drug absorption; * Female patients of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to study entry.Male patients must use at least one reliable form of contraception during treatment and within 3 months after treatment; * Patients have provided a signed Informed Consent Form. Exclusion Criteria: * Experience of Anti-EGFR Monoclonal Antibody or small molecular compounds therapy such as gefitinib, cetuximab, erlotinib or trastuzumab; * Concomitant use with phenytoin, carbamazepine, rifampicin, phenobarbital or St. John's Wort; * Allergic to icotinib or any of the excipients of this product. * Prior chemotherapy with any paclitaxel agents; * Central nervous system (CNS) metastases without radiotherapy and/or surgery; * Evidence of clinically active Interstitial lung diseases; * Severe systemic disease out of control such as unstable or uncompensated respiratory,cardiac,liver,renal diseases; * Patient has a concurrent malignancy or has a malignancy within 5 years of study enrollment, (with the exception of non melanoma skin cancer or cervical carcinoma in situ); * Psychiatric illness that would prevent the patient from giving informed consent; * Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study; * Patient is concurrently using other approved or investigational antineoplastic agent; * Pregnant or lactating women; * Positive epidermal growth factor receptor mutation.